Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage

Oncogene

Volumn 27, Issue 51, 2008, Pages 6590-6595

  Rebillard, A ^a,b   Rioux Leclercq, N ^c,d   Muller, C ^a   Bellaud, P ^c   Jouan, F ^d   Meurette, O ^a,b   Jouan, E ^a,b   Vernhet, L ^a,b   Le Quement C ^a,b   Carpinteiro, A ^e   Schenck, M ^e   Lagadic Gossmann, D ^a,b   Gulbins, E ^e   Dimanche Boitrel, M T ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c Rennes University   (France)

^d UNIVERSITÉ DE RENNES 1   (France)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Acid sphingomyelinase; Cisplatin; Endothelial cells; p53; Small intestine

Indexed keywords

CISPLATIN; SPHINGOMYELIN PHOSPHODIESTERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME DEFICIENCY; GASTROINTESTINAL TOXICITY; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; THYMUS; TISSUE INJURY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; CYTOPROTECTION; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; GENES, P53; INTESTINAL MUCOSA; MICE; MICE, KNOCKOUT; SPHINGOMYELIN PHOSPHODIESTERASE;

MUS;

EID: 55249110643     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.257     Document Type: Article

References (19)

1. Allan SG, Smyth JF. (1986). Small intestinal mucosal toxicity of cis-platinum - comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 53: 355-360.
2. Bezombes C, Grazide S, Garret C, Fabre C, Quillet-Mary A, Muller S et al. (2004). Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. Blood 104: 1166-1173.
3. Grunicke H, Hofmann J. (1992). Cytotoxic and cytostatic effects of antitumor agents induced at the plasma membrane level. Pharmacol Ther 55: 1-30.
4. Gulbins E, Grassme H. (2002). Ceramide and cell death receptor clustering. Biochim Biophys Acta 1585: 139-145.
5. Gulbins E, Kolesnick R. (2003). Raft ceramide in molecular medicine. Oncogene 22: 7070-7077.
6. Harrison Jr SD. (1981). Toxicologic evaluation of cis- diamminedichloroplatinum II in B6D2F1 mice. Fundam Appl Toxicol 1: 382-385.
7. Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, Sandhoff K et al. (1995). Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nat Genet 10: 288-293.
8. Huang C, Ma W, Ding M, Bowden GT, Dong Z. (1997). Direct evidence for an important role of sphingomyelinase in ultraviolet-induced activation of c-Jun N-terminal kinase. J Biol Chem 272: 27753-27757.
9. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O et al. (2004). Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 64: 3593-3598.
10. Loehrer PJ, Einhorn LH. (1984). Drugs five years later. Cisplatin. Ann Intern Med 100: 704-713.
11. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A et al. (2000). Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 6: 1109-1114.
12. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D et al. (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297.
13. Pena LA, Fuks Z, Kolesnick RN. (2000). Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 60: 321-327.
14. Prestayko AW, Bradner WT, Huftalen JB, Rose WC, Schurig JE, Cleare MJ et al. (1979). Antileukemia (L1210) activity and toxicity of cis-dichlorodiammineplatinum(II) analogs. Cancer Treat Rep 63: 1503-1508.
15. Rebillard A, Tekpli X, Meurette O, Sergent O, Le Moigne-Muller G, Vernhet L et al. (2007). Cisplatin-induced apoptosis involves membrane fluidification via inhibition of NHE1 in human colon cancer cells. Cancer Res 67: 7865-7874.
16. Sansom OJ, Clarke AR. (2002). The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. Oncogene 21: 5934-5939.
17. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M et al. (1996). Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 86: 189-199.
18. Tamaki T, Naomoto Y, Kimura S, Kawashima R, Shirakawa Y, Shigemitsu K et al. (2003). Apoptosis in normal tissues induced by anti-cancer drugs. J Int Med Res 31: 6-16.
19. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. (1996). Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 50: 1536-1540.